Bilaal.Raja
Company record

INO  INOVIO PHARMACEUTICALS, INC.

Trailing twelve months to 2026-03-31, as filed 2026-05-13 and not restated since.
Healthcare

Scale

Market cap
$139m
Revenue TTM
$0m
Net income TTM
$-85m
Free cash flow
$-84m
Composite score
Sector rank
#2982

Valuation

P / E
EV / EBITDA
EV / sales
FCF yield
-60.09%
Yield vs 10-yr
-65.84pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.79% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
EBITDA margin
ROE
-1,399.7%
ROIC
Revenue growth
-100.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total revenue was $0 for both the three and six months ended June 30, 2026, as compared to $0 and $65,000 for the three and six months ended June 30, 2025, respectively, all of which was derived under the collaborative arrangement with ApolloBio. The decrease in research and development expenses for the three-month period year over year was primarily the result of: • $1.5 million in lower employee and consultant compensation, including stock-based compensation; • $1.4 million in lower engineering professional and outside services related to our device development; and • $556,000 of lower expensed inventory. …INOVIO PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →